与使用阿司匹林在慢性阻塞性肺病中相关的高风险不良事件
Xiaohua Li1,2, Bin Dai3, Qingbing Han1
1Department of Respiratory and Critical Care Medicine, West China Hospital, West China School of Medicine, and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China.
Expert review of respiratory medicine
|December 13, 2023
概括
在慢性阻塞性肺病 (COPD) 患者中使用阿司匹林与疲劳和腹等不良事件有关. 这项研究确定了COPD患者中阿司匹林相关的十大不良药物事件 (ADEs),以确保更安全的临床使用.
科学领域:
- 药物监督 药物监督 药物监督
- 肺部病理学 肺部病理学
- 临床药理学 临床药理学
背景情况:
- 阿司匹林经常被处方给患有慢性阻塞性肺病 (COPD) 的患者.
- 有限的研究存在阿司匹林的不良影响 (AEs),特别是在COPD人口.
- 了解这些AE对于优化COPD管理至关重要.
研究的目的:
- 在COPD患者中识别和描述与阿司匹林使用相关的不良药物事件 (ADEs).
- 提供支持阿司匹林在COPD管理中更安全的临床利用的数据.
主要方法:
- 对2013年第一季度至2022年第二季度的美国食品和药物管理局不良事件报告系统 (FAERS) 数据的回顾性分析.
- 根据阿司匹林使用情况,COPD患者被分组.
- 统计方法包括报告几率比率 (ROR),比例报告比率 (PRR) 和信息组件 (IC) 用于识别ADEs.
主要成果:
- 总共分析了COPD患者的56660份ADE报告.
- 在COPD患者中,有144个不良事件与阿司匹林使用有关.
- 最多报告的不良事件包括疲劳,腹,运动性呼吸不全,鼻,体重增加,吐,肌肉,心脏疾病,心率增加和周围胀.
- 亚组分析表明,年龄和性别对ADE频率的潜在影响.
结论:
- 在COPD患者中确定了与阿司匹林相关的10个最常见的ADEs.
- 这些发现为阿司匹林在COPD管理中的更安全的临床应用提供了宝贵的见解.
- 强调需要继续监测阿司匹林在这个患者群体中的安全性.
相关概念视频
01:22Chronic Obstructive Pulmonary Disease
1.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.3K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.8K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.8K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
187
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
187
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
526
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526
01:26COPD: Management Using Bronchodilators and Corticosteroids
213
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
213